WO1998011888A1 - Method of treating urinary incontinence - Google Patents
Method of treating urinary incontinence Download PDFInfo
- Publication number
- WO1998011888A1 WO1998011888A1 PCT/US1997/016509 US9716509W WO9811888A1 WO 1998011888 A1 WO1998011888 A1 WO 1998011888A1 US 9716509 W US9716509 W US 9716509W WO 9811888 A1 WO9811888 A1 WO 9811888A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- agent
- incontinent
- cyclobut
- methyl
- propylamino
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP97942538A EP0927034A1 (en) | 1996-09-19 | 1997-09-17 | Method of treating urinary incontinence |
AU44216/97A AU4421697A (en) | 1996-09-19 | 1997-09-17 | Method of treating urinary incontinence |
JP10514847A JP2001502302A (en) | 1996-09-19 | 1997-09-17 | How to treat urinary incontinence |
CA002266070A CA2266070A1 (en) | 1996-09-19 | 1997-09-17 | Method of treating urinary incontinence |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US72426396A | 1996-09-19 | 1996-09-19 | |
US08/724,263 | 1996-09-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998011888A1 true WO1998011888A1 (en) | 1998-03-26 |
Family
ID=24909720
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1997/016509 WO1998011888A1 (en) | 1996-09-19 | 1997-09-17 | Method of treating urinary incontinence |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP0927034A1 (en) |
JP (1) | JP2001502302A (en) |
KR (1) | KR20010029519A (en) |
AU (1) | AU4421697A (en) |
CA (1) | CA2266070A1 (en) |
WO (1) | WO1998011888A1 (en) |
ZA (1) | ZA978427B (en) |
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000012069A1 (en) * | 1998-08-27 | 2000-03-09 | Pharmacia & Upjohn Ab | Therapeutic formulation for administering tolterodine with controlled release |
WO2002045711A1 (en) * | 2000-12-07 | 2002-06-13 | Arakis Ltd. | Use of anti-muscarinic agents and calcium channel blockers in combination |
WO2002047676A1 (en) * | 2000-12-15 | 2002-06-20 | Medicare Management Consultancy Limited | Topical composition and method for treating urinary stress incontinence |
DE10103262A1 (en) * | 2001-01-25 | 2002-08-01 | Axel Schmidt-Dossi | Suppository containing oxybutynin, useful for treatment of incontinence, avoids side effects and allows an increase in dose |
US6436428B1 (en) | 2000-03-21 | 2002-08-20 | Enhance Pharmaceuticals, Inc. | Device and method for treating urinary incontinence in females |
US6630162B1 (en) | 1999-11-11 | 2003-10-07 | Pharmacia Ab | Pharmaceutical formulation and its use |
WO2004014360A2 (en) * | 2002-08-07 | 2004-02-19 | R & D Pharma | Pharmaceutical compositions for the treatment of urinary incontinence |
WO2004043429A1 (en) * | 2002-11-12 | 2004-05-27 | Pharmacia & Upjohn Company | Combination therapy for postmenopausal female sexual dysfunction comprising an androgen, and at least one agent selected from an estrogen and an anti-muscarinic |
US6773421B2 (en) | 2001-12-14 | 2004-08-10 | Kimberly-Clark Worlwide, Inc. | Combination for managing the involuntary loss of bladder control |
EP1455697A1 (en) * | 2001-12-20 | 2004-09-15 | Femmepharma, Inc. | Vaginal delivery of drugs |
EP1465563A1 (en) * | 2001-12-21 | 2004-10-13 | Duramed Pharmaceuticals, Inc. | METHOD OF SYSTEMICALLY DELIVERING SSRIs |
WO2004108645A1 (en) * | 2003-06-05 | 2004-12-16 | Hormos Medical Corporation | Method for the treatment or prevention of lower urinary tract symptoms |
WO2005060955A1 (en) * | 2003-11-27 | 2005-07-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition comprising a beta-3-adrenoceptor agonist and an agent intervening in the prostaglandin metabolism |
JP2005523239A (en) * | 2001-10-02 | 2005-08-04 | キンバリー クラーク ワールドワイド インコーポレイテッド | Suppression of exoprotein production using aromatic compounds |
US7696357B2 (en) * | 2002-03-26 | 2010-04-13 | Novartis International Pharmaceutical Ltd. | Stable hydrate of a muscarinic receptor antagonist |
US7812010B2 (en) | 2003-01-02 | 2010-10-12 | Femmepharma, Inc. | Pharmaceutical preparations for treatments of diseases and disorders of the breast |
US7825107B2 (en) | 2006-05-22 | 2010-11-02 | Hormos Medical Ltd. | Method of treating men suffering from chronic nonbacterial prostatitis with SERM compounds or aromatase inhibitors |
WO2011005709A2 (en) | 2009-07-06 | 2011-01-13 | Femmepharma Holding Company, Inc. | Transvaginal delivery of drugs |
US9173836B2 (en) | 2003-01-02 | 2015-11-03 | FemmeParma Holding Company, Inc. | Pharmaceutical preparations for treatments of diseases and disorders of the breast |
WO2015187183A1 (en) * | 2014-06-06 | 2015-12-10 | Wellesley Pharmaceuticals, Llc | Pharmaceutical formulation for reducing frequency of urination and method of use thereof |
US9532959B2 (en) | 2010-07-08 | 2017-01-03 | Wellesley Pharmaceuticals, Llc | Pharmaceutical formulation for reducing frequency of urination and method of use thereof |
US10010514B2 (en) | 2010-07-08 | 2018-07-03 | Wellesley Pharmaceuticals, Llc | Pharmaceutical formulation for reducing frequency of urination and method of use thereof |
US10105328B2 (en) | 2014-06-06 | 2018-10-23 | Wellesley Pharmaceuticals, Llc | Composition for reducing frequency of urination, method of making and use thereof |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201601855D0 (en) * | 2016-02-02 | 2016-03-16 | Inura Medical Ag | Urethral devices for treatment of pathological urological conditions |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0445749A1 (en) * | 1990-03-08 | 1991-09-11 | Fujisawa Pharmaceutical Co., Ltd. | N-Monosubstituted cyclopentenylamines, a process for their preparation and their use as medicaments |
EP0534756A2 (en) * | 1991-09-27 | 1993-03-31 | Eli Lilly And Company | N-alkyl-3-phenyl-3-(2-halo-substituted phenoxy)propylamines as norepinephrine uptake inhibiteurs |
WO1993008800A1 (en) * | 1991-11-07 | 1993-05-13 | New York University | Potassium channel activating compounds and methods of use thereof |
EP0546547A1 (en) * | 1991-12-10 | 1993-06-16 | Hoechst Japan Limited | Pharmaceutical composition for the improvement of dysuria |
EP0617010A1 (en) * | 1993-03-15 | 1994-09-28 | Zeneca Limited | Therapeutic compounds |
GB2278054A (en) * | 1993-05-18 | 1994-11-23 | Zeneca Ltd | Compounds for the treatment of urinary incontinence |
US5441950A (en) * | 1994-06-09 | 1995-08-15 | G. D. Searle & Co. | Substituted dibenzoxazepine and dibenzthiazepine carbamate compounds, pharmaceutical compositions and methods of use |
WO1996005817A1 (en) * | 1994-08-23 | 1996-02-29 | Medinnova Sf | Medicament for treatment or prophylaxis of incontinence |
WO1996023492A1 (en) * | 1995-01-31 | 1996-08-08 | Sepracor, Inc. | Treating urinary incontinence using (s)-oxybutynin and (s)-desethyloxybutynin |
WO1997009980A1 (en) * | 1995-09-15 | 1997-03-20 | Pfizer Research And Development Company, N.V./S.A. | Pharmaceutical formulations containing darifenacin |
-
1997
- 1997-09-17 JP JP10514847A patent/JP2001502302A/en active Pending
- 1997-09-17 AU AU44216/97A patent/AU4421697A/en not_active Abandoned
- 1997-09-17 CA CA002266070A patent/CA2266070A1/en not_active Abandoned
- 1997-09-17 WO PCT/US1997/016509 patent/WO1998011888A1/en not_active Application Discontinuation
- 1997-09-17 KR KR1019997002314A patent/KR20010029519A/en not_active Application Discontinuation
- 1997-09-17 EP EP97942538A patent/EP0927034A1/en not_active Withdrawn
- 1997-09-18 ZA ZA978427A patent/ZA978427B/en unknown
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0445749A1 (en) * | 1990-03-08 | 1991-09-11 | Fujisawa Pharmaceutical Co., Ltd. | N-Monosubstituted cyclopentenylamines, a process for their preparation and their use as medicaments |
EP0534756A2 (en) * | 1991-09-27 | 1993-03-31 | Eli Lilly And Company | N-alkyl-3-phenyl-3-(2-halo-substituted phenoxy)propylamines as norepinephrine uptake inhibiteurs |
WO1993008800A1 (en) * | 1991-11-07 | 1993-05-13 | New York University | Potassium channel activating compounds and methods of use thereof |
EP0546547A1 (en) * | 1991-12-10 | 1993-06-16 | Hoechst Japan Limited | Pharmaceutical composition for the improvement of dysuria |
EP0617010A1 (en) * | 1993-03-15 | 1994-09-28 | Zeneca Limited | Therapeutic compounds |
GB2278054A (en) * | 1993-05-18 | 1994-11-23 | Zeneca Ltd | Compounds for the treatment of urinary incontinence |
US5441950A (en) * | 1994-06-09 | 1995-08-15 | G. D. Searle & Co. | Substituted dibenzoxazepine and dibenzthiazepine carbamate compounds, pharmaceutical compositions and methods of use |
WO1996005817A1 (en) * | 1994-08-23 | 1996-02-29 | Medinnova Sf | Medicament for treatment or prophylaxis of incontinence |
WO1996023492A1 (en) * | 1995-01-31 | 1996-08-08 | Sepracor, Inc. | Treating urinary incontinence using (s)-oxybutynin and (s)-desethyloxybutynin |
WO1997009980A1 (en) * | 1995-09-15 | 1997-03-20 | Pfizer Research And Development Company, N.V./S.A. | Pharmaceutical formulations containing darifenacin |
Non-Patent Citations (4)
Title |
---|
ANONYM: "ACOG technical bulletin : Urinary incontinence", INT. J. GYNECOL. OBSTET., vol. 52, no. 1, January 1996 (1996-01-01), pages 75 - 86, XP002050836 * |
ROUSSEAU: "Urinary incontinence in the aged, Part 2: management strategies", GERIATRICS, vol. 47, no. 6, 1992, pages 37 - 48, XP002050834 * |
SCHONBERGER: "Adrenerg oder cholinerg gegen "nasse Nächte" ?", KRANKENHAUS ARTZ, vol. 68, no. 1-2, 1995, pages 12 - 17, XP002050835 * |
WALTERS: "The evaluation and treatment of urinary incontinence in women : a primary care approach", J. AM. BOARD PRACT., vol. 5, no. 3, 1992, pages 289 - 301, XP002050837 * |
Cited By (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU745190B2 (en) * | 1998-08-27 | 2002-03-14 | Pharmacia & Upjohn Ab | Therapeutic formulation for administering tolterodine with controlled release |
US6770295B1 (en) | 1998-08-27 | 2004-08-03 | Pharmacia Ab | Therapeutic formulation for administering tolterodine with controlled release |
AP1529A (en) * | 1998-08-27 | 2006-01-03 | Pharmacia & Upjohn Ab | Therapeutic formulation for administering tolterodine with controlled release. |
EP2153825A1 (en) * | 1998-08-27 | 2010-02-17 | Pfizer Health AB | Therapeutic formulation for administering tolterodine with controlled release |
WO2000012069A1 (en) * | 1998-08-27 | 2000-03-09 | Pharmacia & Upjohn Ab | Therapeutic formulation for administering tolterodine with controlled release |
US6630162B1 (en) | 1999-11-11 | 2003-10-07 | Pharmacia Ab | Pharmaceutical formulation and its use |
EP1278494A1 (en) * | 2000-03-21 | 2003-01-29 | Enhance Pharmaceuticals, Inc. | Device and method for treating urinary incontinence in females |
JP2003527404A (en) * | 2000-03-21 | 2003-09-16 | エンハンス ファーマシューティカルズ,インコーポレイティド | Devices and methods for treating urinary incontinence in women |
EP1278494A4 (en) * | 2000-03-21 | 2005-11-02 | Duramed Pharmaceuticals Inc | Device and method for treating urinary incontinence in females |
EP2106785A1 (en) * | 2000-03-21 | 2009-10-07 | Duramed Pharmaceuticals, Inc. | Device and method for treating urinary incontinence in females |
US6436428B1 (en) | 2000-03-21 | 2002-08-20 | Enhance Pharmaceuticals, Inc. | Device and method for treating urinary incontinence in females |
JP2013107895A (en) * | 2000-03-21 | 2013-06-06 | Teva Women's Health Inc | Device and method for treating urinary incontinence in female |
WO2002045711A1 (en) * | 2000-12-07 | 2002-06-13 | Arakis Ltd. | Use of anti-muscarinic agents and calcium channel blockers in combination |
KR100879656B1 (en) | 2000-12-15 | 2009-01-20 | 플레토라 솔루션즈 리미티드 | Topical composition and method for treating urinary stress incontinence |
WO2002047676A1 (en) * | 2000-12-15 | 2002-06-20 | Medicare Management Consultancy Limited | Topical composition and method for treating urinary stress incontinence |
AU2002222221B2 (en) * | 2000-12-15 | 2006-11-30 | Plethora Solutions Limited | Topical composition and method for treating urinary stress incontinence |
DE10103262A1 (en) * | 2001-01-25 | 2002-08-01 | Axel Schmidt-Dossi | Suppository containing oxybutynin, useful for treatment of incontinence, avoids side effects and allows an increase in dose |
JP2005523239A (en) * | 2001-10-02 | 2005-08-04 | キンバリー クラーク ワールドワイド インコーポレイテッド | Suppression of exoprotein production using aromatic compounds |
US6773421B2 (en) | 2001-12-14 | 2004-08-10 | Kimberly-Clark Worlwide, Inc. | Combination for managing the involuntary loss of bladder control |
EP1455697A1 (en) * | 2001-12-20 | 2004-09-15 | Femmepharma, Inc. | Vaginal delivery of drugs |
US8226972B2 (en) | 2001-12-20 | 2012-07-24 | Femmepharma Holding Company, Inc. | Vaginal delivery of drugs |
EP1455697A4 (en) * | 2001-12-20 | 2009-08-05 | Femmepharma Holding Co Inc | Vaginal delivery of drugs |
EP1465563A1 (en) * | 2001-12-21 | 2004-10-13 | Duramed Pharmaceuticals, Inc. | METHOD OF SYSTEMICALLY DELIVERING SSRIs |
EP1465563A4 (en) * | 2001-12-21 | 2010-06-30 | Duramed Pharmaceuticals Inc | METHOD OF SYSTEMICALLY DELIVERING SSRIs |
US7696357B2 (en) * | 2002-03-26 | 2010-04-13 | Novartis International Pharmaceutical Ltd. | Stable hydrate of a muscarinic receptor antagonist |
WO2004014360A2 (en) * | 2002-08-07 | 2004-02-19 | R & D Pharma | Pharmaceutical compositions for the treatment of urinary incontinence |
WO2004014360A3 (en) * | 2002-08-07 | 2004-04-08 | R & D Pharma | Pharmaceutical compositions for the treatment of urinary incontinence |
WO2004043429A1 (en) * | 2002-11-12 | 2004-05-27 | Pharmacia & Upjohn Company | Combination therapy for postmenopausal female sexual dysfunction comprising an androgen, and at least one agent selected from an estrogen and an anti-muscarinic |
US9173836B2 (en) | 2003-01-02 | 2015-11-03 | FemmeParma Holding Company, Inc. | Pharmaceutical preparations for treatments of diseases and disorders of the breast |
US7812010B2 (en) | 2003-01-02 | 2010-10-12 | Femmepharma, Inc. | Pharmaceutical preparations for treatments of diseases and disorders of the breast |
AU2004245251B2 (en) * | 2003-06-05 | 2010-10-07 | Hormos Medical Corporation | Method for the treatment or prevention of lower urinary tract symptoms |
US9993442B2 (en) | 2003-06-05 | 2018-06-12 | Hormos Medical Ltd. | Method for the treatment or prevention of lower urinary tract symptoms |
US10780063B2 (en) | 2003-06-05 | 2020-09-22 | Hormos Medical Ltd. | Method for the treatment or prevention of lower urinary tract symptoms |
WO2004108645A1 (en) * | 2003-06-05 | 2004-12-16 | Hormos Medical Corporation | Method for the treatment or prevention of lower urinary tract symptoms |
US8962693B2 (en) | 2003-06-05 | 2015-02-24 | Hormos Medical Ltd. | Method for the treatment or prevention of lower urinary tract symptoms |
US9114106B2 (en) | 2003-06-05 | 2015-08-25 | Hormos Medical Ltd. | Method for the treatment or prevention of lower urinary tract symptoms |
WO2005060955A1 (en) * | 2003-11-27 | 2005-07-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition comprising a beta-3-adrenoceptor agonist and an agent intervening in the prostaglandin metabolism |
US7825107B2 (en) | 2006-05-22 | 2010-11-02 | Hormos Medical Ltd. | Method of treating men suffering from chronic nonbacterial prostatitis with SERM compounds or aromatase inhibitors |
WO2011005709A2 (en) | 2009-07-06 | 2011-01-13 | Femmepharma Holding Company, Inc. | Transvaginal delivery of drugs |
US9532959B2 (en) | 2010-07-08 | 2017-01-03 | Wellesley Pharmaceuticals, Llc | Pharmaceutical formulation for reducing frequency of urination and method of use thereof |
US10010514B2 (en) | 2010-07-08 | 2018-07-03 | Wellesley Pharmaceuticals, Llc | Pharmaceutical formulation for reducing frequency of urination and method of use thereof |
WO2015187183A1 (en) * | 2014-06-06 | 2015-12-10 | Wellesley Pharmaceuticals, Llc | Pharmaceutical formulation for reducing frequency of urination and method of use thereof |
CN106714805A (en) * | 2014-06-06 | 2017-05-24 | 韦尔斯利医药有限公司 | Pharmaceutical formulation for reducing frequency of urination and method of use thereof |
US10105328B2 (en) | 2014-06-06 | 2018-10-23 | Wellesley Pharmaceuticals, Llc | Composition for reducing frequency of urination, method of making and use thereof |
US10130596B2 (en) | 2014-06-06 | 2018-11-20 | Wellesley Pharmaceuticals, Llc | Composition for reducing frequency of urination, method of making and use thereof |
Also Published As
Publication number | Publication date |
---|---|
CA2266070A1 (en) | 1998-03-26 |
KR20010029519A (en) | 2001-04-06 |
EP0927034A1 (en) | 1999-07-07 |
JP2001502302A (en) | 2001-02-20 |
ZA978427B (en) | 1999-06-18 |
AU4421697A (en) | 1998-04-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0927034A1 (en) | Method of treating urinary incontinence | |
Chapple | Muscarinic receptor antagonists in the treatment of overactive bladder | |
KR20110092267A (en) | Aminopyrimidine inhibitors of histamine receptors for the treatment of disease | |
JPS6056973A (en) | Antihistamic with weak sedative activity | |
WO2007096300A1 (en) | Benzimidazolone derivatives for the treatment of urinary incontinence | |
JP2008512462A (en) | Treatment of diseases using nalmefene and analogs thereof | |
GB2196962A (en) | Substituted 2-benzyl-mercapto-imidazoles and analogs useful as anti-inflammatory agents | |
EP0135087B1 (en) | Ethylenediamines | |
MXPA04010934A (en) | Compositions and methods for combating lower urinary tract dysfunctions with delta opioid receptor agonists. | |
JP2001512110A (en) | 1,4-disubstituted piperazine | |
UA79238C2 (en) | Use of derivatives of aryl (or heteroaryl) azolylcarbinoles | |
JPS61172871A (en) | Dibenz(b,e)oxepine or dibenz(b,e)thiepine compound, manufacture and medicin composition | |
DE60127712T2 (en) | SELECTIVE DOPAMINE D4 RECEPTOR AGONISTS FOR THE TREATMENT OF SEXUAL DYSFUNCTIONS | |
RO115519B1 (en) | 1-arylcycloalkyl sulphides, sulphoxides and sulphones, process for preparing the same and pharmaceutical composition containing them | |
US4812480A (en) | Composition for administration through a body cavity | |
JP2002510289A (en) | Indene compound having activity as SERM | |
PL137717B1 (en) | Process for preparing 1-/1,3-benzoolioxol-5-yl/-2-pyrrolidinone | |
US4410527A (en) | Substituted thienobenzodiazepinones and salts thereof | |
CN1031840A (en) | Benzofuran derivative and preparation method thereof | |
EP1341777B1 (en) | 1-(2-m-methanesulfonamidophenylethyl)-4-(m-trifluoromethylphenyl)piperazine and pharmaceutically acceptable salts and solvates thereof and their use in the treatement of incontinence | |
EP0251126B1 (en) | 1,7-substituted heptyne-2-ones | |
KR20050011139A (en) | Process for preparation of the propiverine hydrochloride from O-n-propylbenzylic acid | |
JP2004002248A (en) | Human-originated prostagrandin-synthesizing enzyme inhibitor | |
RU2115411C1 (en) | Rectal suppositorium showing topical anesthetic effect | |
CN102993208A (en) | Noradrenaline and selective serotonin receptor blocking agent and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV GH |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 1998 514847 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1997942538 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2266070 Country of ref document: CA Ref country code: CA Ref document number: 2266070 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1019997002314 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 1997942538 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1997942538 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1019997002314 Country of ref document: KR |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1019997002314 Country of ref document: KR |